Bipolar disorder (BD) is a debilitating mood disorder with no specific biological marker. No novel treatment has been developed specifically for BD in the last several decades. Although the pathophysiology of BD remains unclear, there is strong evidence in the literature supporting the role of mitochondrial dysfunction in BD. In this systematic review, we identified and investigated 12 studies that measure lactate, which is a direct marker for mitochondrial dysfunction, in BD patients and healthy controls. Six studies measured lactate levels in the brain through proton echo-planar spectroscopy or magnetic resonance spectroscopy and five of these studies reported significantly elevated lactate levels in patients with BD. Two studies reporting cerebrospinal fluid lactate levels also found significantly elevated lactate in BD compared to healthy controls. Two other studies that reported peripheral lactate levels did not demonstrate significant findings. The meta-analysis, using standardized means and a random-effect model for five studies that measured brain lactate levels, corroborated the findings of the systematic review. Although the meta-analysis had a nearly significant overall effect (Z = 1.97, P = 0.05), high statistical heterogeneity (I 2 = 86%) and possible publication bias suggest that the results should be interpreted with caution. To validate lactate abnormalities in BD, further studies should be carried out, including larger sample sizes, not excluding female patients, and using standardized methodologies. Peripheral lactate levels and other bioenergetic markers should be thoroughly studied to better understand the role of mitochondrial dysfunction in BD and to help develop more objective diagnostic tools.
B
IPOLAR DISORDER (BD) IS a complex mood disorder affecting over 1% of the global population. 1 This disorder is characterized by fluctuating episodes of mania and depression, which greatly impair patient function and cognition. 1 While a number of pharmacological treatments have been developed, the pathophysiology of BD is still poorly understood. Energy metabolism impairment is a key component in mitochondrial disease and frequently reported in BD. Kato and Kato first proposed the mitochondrial dysfunction hypothesis in September 2000. 2 This theory has been thought to explain the altered neural plasticity and pathophysiology exhibited in the diseased state. 2 A shift from aerobic to anaerobic energy metabolism causes metabolite levels to shift, including lactate. 3 This abnormality is worth noting as lactate is a direct marker for mitochondrial dysfunction and a biomarker used to evaluate a patient's response to treatment. 4 Interestingly, previous literature has shown that lactate is altered in the brain and cerebrospinal fluid (CSF) in patients with BD. 5 These changes have been noted since the late 1950s, when Altschule et al. observed altered lactate levels during manic and depressive episodes. 6 Chu et al. reported decreased lactate levels in several brain regions, including the anterior cingulate cortex (ACC) and the caudate; and Regenold et al. observed increased lactate in the CSF. 7, 8 While many independent studies have demonstrated changes in lactate levels in BD, to the best of our knowledge, no studies have yet combined these individual studies to evaluate the overall trend and effect size of lactate in BD. Thus, a meta-analysis provides a method of systematically assessing the body of evidence while also combining the results from individual studies in potentially increasing power to detect real effects. In the present study, we aim to perform a systematic review and metaanalysis of differences in mean lactate levels between BD and non-psychiatric controls. We focus on lactate because it is a primary criterion when defining mitochondrial disease and would be a strong piece of evidence to support the role of mitochondrial dysfunction in BD. Understanding BD as a matter of possible mitochondrial dysfunction could transform diagnostic and therapeutic techniques. 3 
METHODOLOGY Search strategy
A search strategy protocol was first developed to include all English-language peer-reviewed articles from inception to January 2018 relevant to lactate in BD. The following terms were used to search PubMed: ('bipolar disorder' OR 'bipolar depression' OR 'bipolar mania') and ('lactate' OR 'lactic acid'). Additional articles were also taken into consideration by using the following search terms: ('bipolar disorder' OR 'bipolar depression' OR 'bipolar mania') and ('metabolomics'). Conference abstracts and posters were also taken into consideration for the study as long the content satisfied the selection criteria.
Selection criteria
Articles from the initial search were included if they met the following criteria: (i) the study was a crosssectional case-control or a longitudinal study measuring lactate in whole blood, plasma, serum, CSF, or brain tissue samples from patients with BD according to criteria established in the DSM-5; and (ii) the study presented lactate concentration using mean and SD, sample size, and P-values. All phases of the illness amongst BD patients were included in the study. If relevant data were not provided in the article or its supplementary, the authors of the paper were contacted twice in a 2-week timeframe.
Studies were excluded if they met the following criteria: (i) there was no control group; (ii) the publication was a review article or a book chapter; (iii) the study was an in vitro or in vivo study, as they do not evaluate endogenous human metabolism; (iv) the author failed to reply to requests for additional information; or (v) the same dataset or study population was repeatedly used to avoid overweighing the dataset. In the case where the same datasets were published at different times, the study with the largest sample size was included while the remaining was excluded.
Data abstraction and recorded variables
Data from eligible studies were abstracted independently by two reviewers using a data-extraction spreadsheet with the following headers: PMID, primary author, year of publication, study method and samples, diagnosis of subjects, total number of patients in BD and non-psychiatric control group, and mean and SD of brain lactate necessary for calculation of effect size. Any discrepancies regarding data abstraction were resolved by universal agreement in discussion with a third author. Where any of the above data were not provided, these were requested by contacting the corresponding authors of studies.
selected for the meta-analysis was determined using Cochrane Q-statistic (χ 2 ) and by calculating the tausquared or I 2 statistic, where I 2 of 0.25, 0.50, and 0.75 indicate small, medium, and high heterogeneity, respectively. 9 Publication bias was assessed by visually inspecting funnel plots. All comparisons conducted in this meta-analysis were two-tailed using a 95% confidence interval.
RESULTS

Systematic overview
After applying the inclusion and exclusion criteria to our search results, we identified 12 studies for the systematic review (Table 1) 4,7,8,10-18 and five studies for the meta-analysis (Fig. 1) . 4, 7, 10, 13, 15 Brain imaging for lactate
In 12 studies included for the systematic review, six studies measured brain lactate levels in BD patients and healthy controls (HC). Five of these six studies used 2D proton magnetic resonance spectroscopy (2D 1 H MRS) to quantify lactate levels in many regions of the brain in subjects with BD. The 2D 1 H MRS technique is noninvasive and quantifies metabolite concentrations in vivo by utilizing magnetic resonance signals detected from the nuclei of hydrogen atoms. 19 One study used proton echo-planar spectroscopic imaging (PEPSI), which is another form of spectroscopic imaging that allows for the quantification of brain metabolites at high sensitivity and with lipid suppression. 20 We also included two studies that reported on CSF lactate levels in BD patients compared to HC. Details of the findings are described below.
Studies demonstrating increase in lactate
Of the six papers that reported on brain lactate levels, five demonstrated increased levels of lactate in the brain of BD patients compared to HC. Below, we describe the four MRS studies and one PEPSI study, in addition to two CSF studies, which all demonstrated greater lactate levels in BD.
A recent MRS study by Machado-Vieira et al. assessed lactate levels in the cingulate cortex of BD depressed patients (80% drug-naïve [n = 16], and 20% drug-free [n = 4] for 6 months) and 16 nonpsychiatric HC and found significantly higher lactate levels (P = 0.04) in BD patients (n = 20) compared to HC. 4 In the same study, MachadoVieira et al. also compared the cingulate cortex lactate levels pre-and post-lithium treatment (6 weeks). 4 Cingulate cortex lactate was significantly lower (P = 0.002) post-lithium treatment, and there was no difference compared to the cingulate cortex lactate in HC. 4 In another MRS study, Soeiro-de-Souza et al. found significantly higher lactate levels (P = 0.02) in the dorsal ACC of euthymic BD type I patients (n = 37) compared to HC (n = 35). 10 Interestingly, a positive correlation (P = 0.003) between lactate and glutathione levels was only observed in BD patients, but BD patients (n = 50) did not have significantly higher levels of glutathione (P = 0.08) compared to HC (n = 38). 10 As glutathione is the primary antioxidant in the brain, Soeiro-de-Souza et al. proposed that the correlation between glutathione and lactate in BD patients indicated a greater level of compensatory response to mitochondrial dysfunction. 10 In contrast to the study by Machado-Vieira et al., 4 the BD patients in the Soeiro-de-Souza et al. study were on stable medication regimens. 10 It should also be noted that 13 BD patients and three HC were excluded from the study by Soeiro-de-Souza et al. due to contamination of lipids or other artifacts.
Chu et al. observed MRS lactate levels (as ratios, lactate/N-acetylaspartate and lactate/[phosphocreatine + creatine]) in the ACC, caudate, posterior cingulate, parietal cortex, and insula. 7 The study included 21 BD patients (n = 16 euthymic, n = 5 mixed) and 10 HC. 7 However, only nine BD patients (n = 7 euthymic, n = 2 mixed) and three HC presented lactate signals. 7 In addition, lactate signals in the ACC, posterior cingulate, and insula were only observed in BD patients. 7 The study found statistically significantly greater lactate (P = 0.04 for lactate/N-acetylaspartate, and P = 0.04 for lactate/[phosphocreatine + creatine]) in BD patients compared to HC. 7 It is unclear why lactate signal was only detected in 42.86% of BD patients, but possible factors could include differences in the mood state, medication status (seven patients were medication-free) and type, and the MRSI parameters. Xu et al. reported similar findings in an MRS study of medication-free depressive (n = 12) and manic (n = 12) BD patients. 12 In the anterior and posterior cingulate cortex and the thalamus, BD patients (n = 24) had significantly higher levels of lactate (measured as lactate/creatine ratio, P = 0.02) than HC (n = 20). 15 Further analysis revealed higher grey matter lactate in BD type I patients (n = 11; P = 0.001) but not BD type II patients (n = 17; P = 0.1). 15 No statistically significant difference in lactate was found in white matter. 15 In a follow-up study, Friedman et al. studied the effect of lithium and valproic acid treatment on the same subset of BD patients. 14 Compared to untreated HC (n = 12), there were no statistically significant differences in grey matter lactate of BD patients treated with lithium (n = 12) or valproic acid (n = 9). 14 In agreement with the MRS and PEPSI studies, Regenold et al. (using SYI 23000 STAT Plus Glucose & Lactate Analyzer) found significantly greater lactate (P = 0.001) in the CSF of BD type I patients (n = 15; n = 11 manic, n = 4 depressed) than HC (n = 15). 8 CSF lactate was also assessed in a metabolomics study by Yoshimi et al. 17 In this study of all male subjects, BD patients (n = 54) had significantly greater CSF lactate levels (P = 0.006) than HC (n = 40). 17 No change or decrease in lactate Brady et al. evaluated MRS lactate levels (as lactate/ creatine ratio) in the ACC and parietal occipital cortex of BD patients (n = 7) hospitalized for mania. 13 Lactate was measured during mania and euthymia of the same patient. 13 In comparison to HC (n = 6), manic BD patients had similar lactate levels and euthymic BD patients had lower lactate levels (P = 0.049). 13 In addition, the lactate levels in BD mania were significantly greater than the levels in BD euthymia (P = 0.002). 13 The results of this study suggest a possible relation between mitochondrial dysfunction and mood state in BD.
Peripheral lactate
Only two studies from our search reported on lactate levels in the periphery. Elmorsy et al. measured blood lactate levels in patients with BD (n = 56) or schizophrenia (n = 32). 11 Compared to HC (n = 28), the arterial blood lactate levels did not differ significantly (P = 0.06) in BD and schizophrenia patients. 11 However, Elmorsy et al. observed increase in blood lactate levels in response to treatment with antipsychotics and its extrapyramidal side-effects. 11 Although the results suggest that peripheral lactate may not be a biomarker for baseline BD or schizophrenia, the study did not separate patients with BD and schizophrenia. The study also excluded female patients on the basis that lactate levels can fluctuate with the menstrual cycle. 21 Using 1 H nuclear magnetic resonance (NMR) spectroscopy, Domino et al. found greater levels of lactate in red blood cells of lithiumtreated BD patients (n = 18) compared to HC (n = 12). 16 However, this result is likely confounded by the blood standing at room temperature, in which elevated lactate was also observed via 1 H NMR analysis. In a metabolomics study that also used only male patients and HC, Yoshimi et al. reported elevated mean serum lactate, though not significant (P = 0.321), for BD patients (n = 54) in comparison to HC (n = 40). 18 This study used the same subject population as another Yoshimi et al. article, which reported significantly elevated CSF lactate in BD and was covered above in the section titled 'Studies demonstrating increase in lactate.' 17 It is worth noting that when evaluating peripheral lactate, we should not directly compare the study of rapid measurement 10 Heterogeneity. Tau 2 = 0.00; χ 2 = 27.77, df = 4 (P < 0.0001); I 2 = 86% Test for overall effect: Z = 1.97 (P = 0.05) 
Meta-analysis
Six papers were identified for the meta-analysis; however, only five were included. Xu et al. did not include the mean and SD for each group, and was therefore not included in the meta-analysis. 12 From the five papers included in the meta-analysis, we found a near significant difference (P = 0.05) in the brain lactate levels of BD patients compared to HC (Fig. 2) . This result appears to correspond to the findings in our systematic review, where we reported that five studies had nearly significant higher brain lactate levels in BD patients, compared to HC. Although results of the meta-analysis revealed that the overall effect (Z = 1.97, P = 0.05) was near significance, there was high statistical heterogeneity (I 2 = 86%) among the studies included (Fig. 2) . Due to the small number of studies included in the meta-analysis, publication bias was assessed by visually inspecting the funnel plot (Fig. 3) . Three of the five studies appear to be similar based on the study size and effect size. The asymmetry of the funnel plot suggests that there may be publication bias. This is also evident in the empty bottom left of the funnel plot, indicating a lack of small studies with negative results. Therefore, the results of the meta-analysis, which appears to suggest a trend towards increased brain lactate levels in BD, should be interpreted with caution.
DISCUSSION
In this systematic review and meta-analysis, we incorporated evidence from a total of six studies, comprising a total of 117 patients with BD and 93 non-psychiatric controls. We showed that in comparison to HC, lactate levels were elevated in the brains of BD patients. Of the six studies included in our meta-analysis on brain lactate levels, five reported increased lactate levels in BD, while one study reported similar and decreased lactate levels for manic and euthymic BD patients, respectively. Interestingly, studies by Machado-Vieira et al. 4 and Friedman et al.
14 demonstrated similar brain lactate levels in BD patients post-medication (lithium for patients in the study by Machado-Vieira et al.; lithium or valproate in the study by Friedman et al.) and HC. The baseline lactate levels of these same BD patients prior to taking lithium or valproate were elevated compared to HC. 4, 15 Accordingly, the results of these studies suggest that medication may be able to restore brain lactate levels to a degree comparable to the levels in HC. While the robustness of the overall findings appears to be weak, as indicated by the small effect size, there was nevertheless a relatively consistent trend towards elevated brain lactate levels reported in most of the studies included in this systematic review, suggesting that mitochondrial function may be impaired in patients with BD. Recently, Dogan et al. published a qualitative synthesis of brain lactate and pH in BD and schizophrenia patients. 22 Dogan et al. reported the same brain imaging studies and found a similar trend of elevated lactate in BD. 22 Beyond the systematic review reported here, our quantitative evaluation of lactate through a metaanalysis revealed a nearly significant increase in lactate, corroborating the findings in the Dogan et al. paper and supporting the mitochondrial dysfunction hypothesis in BD.
Interestingly, elevated (or abnormal) levels of lactate have been detected in the peripheries, CSF, and brains of patients with mitochondrial diseases. 23 It has been noted that CSF lactate levels may be more reliable than peripheral lactate levels for mitochondrial disease patients that present neurological symptoms. 23 The findings in the mitochondrial disease literature demonstrate some overlap with the findings of our systematic review and meta-analysis, further suggesting the possible of role of mitochondrial dysfunction in BD. Despite these similarities, it is important for future studies to evaluate and identify the differences in lactate among BD and mitochondrial disease patients, as well as HC. Our results should be interpreted in light of several limitations. One major limitation in the present study is the high heterogeneity among studies. For studies included in the meta-analysis, the patient populations differed in their age, onset of illness, number of mood episodes, BD phenotype, medication status, illness phase during the MRS or PEPSI scans, brain region imaged, and geographical location, which can reflect differences in diet and lifestyles. For example, there is evidence that medication could alter brain lactate levels in BD. 4, 14, 15 Although Machado-Vieira et al., 4 Xu et al., 12 and Dager et al. 15 reported on medicationfree/naïve patients, Soeiro-de-Souza et al. 10 and Brady et al. 13 reported on patients with stable medication regimens, and Chu et al. reported on both medication-free and medication-using patients. 7 Interestingly, Dager et al. found significant elevated brain lactate levels in type I but not in type II BD patients. 15 Soeiro-de-Souza et al. also found significantly increased brain lactate in type I BD. 10 In addition, the metabolomics study by Yoshimi et al. supports these findings with elevated CSF lactate in male type I BD patients. 17 Elevated brain lactate has been reported in BD patients in different mood states, but Brady et al. reported findings that contradict this. 13 Not only were brain lactate levels in manic BD patients similar to HC, but euthymic BD patients were reported to have significantly lower brain lactate than HC. These findings may suggest a possible relation between lactate levels or mitochondrial dysfunction and mood state in BD. It should also be noted that patients in the Brady et al. study were diagnosed with BD type I and hospitalized for acute mania, 13 both of which may contribute to findings that may be inconsistent with the other studies. Dager et al. is the only group in our meta-analysis that used PEPSI, rather than MRS, to measure and quantify brain lactate. 15 However, we performed our meta-analysis without the study by Dager et al. and obtained the same I 2 statistical value (i.e. I 2 = 86%; Fig.ure S1 ). This suggests that the imaging techniques (i.e., MRS and PEPSI) may not be the only cause of heterogeneity. Therefore, the high statistical heterogeneity (I 2 = 86%), which suggests great variability between the studies included in the meta-analysis, may be more attributable to medication status and mood state. Although high statistical heterogeneity can limit interpretations of the results, it is also a major finding of the meta-analysis -suggesting a need for more standardized brain imaging studies of lactate levels in BD. Other limitations of this metaanalysis and systematic review include the paucity of studies on brain lactate in BD and publication bias.
Although the results of the meta-analysis revealed a nearly significant overall effect of brain lactate in BD, the effect size is relatively weak -possibly due to the paucity of studies. Only five studies were found to assess brain lactate levels, and the paucity of findings in the grey literature could contribute to publication bias. Therefore, the limitations of this systematic review and meta-analysis suggest that the findings should be evaluated with caution. Energetic systems tend to be tissue-specific -that is, brain lactate levels may only be indicative of the metabolic state in the brain. Although lactate levels in the blood may not be representative of the metabolic state in the brain, not much is known about whether metabolic abnormalities occur in the periphery of BD patients. Searching for possible metabolic abnormalities in the blood of BD patients could lead to the identification of biomarkers, which could be easily assessed and used for objective BD diagnosis. Our systematic review also revealed the paucity of studies reporting peripheral lactate levels in BD. Of the three studies included in the systematic review, only Domino et al. reported a significant lactate increase in the red blood cells of lithiumtreated BD patients and this increase is likely confounded by the fact that the blood sat at room temperature. 16 Interestingly, the other two studies 11, 18 that did not report any significant differences in the peripheral lactate levels in BD compared to HC, excluded female participants. For these reasons, it is difficult to draw conclusions from the peripheral lactate data in BD. The paucity of available evidence in the literature posits the need for more studies that assess lactate levels in the peripheries of BD patients and studies that are more inclusive and representative of the BD patient population. Future studies should consider measuring lactate levels in the brain and periphery in different BD subtypes and in those drug-free, drug-naïve, and medicated in order to better elucidate the role of lactate in BD. Currently, the diagnosis of BD is based on subjective measures, such as the medical history, interviews, and behavioral observations of the patient. There is need for objective measures, such as the use of biomarkers, to prevent misdiagnosis and allow doctors to provide appropriate treatment options for patients with BD. As such, if findings of peripheral lactate levels are in agreement with the findings of brain lactate levels, then there may be a possibility to employ peripheral lactate as a biomarker for BD. Also, if we continue to validate increased lactate in the blood from patients with BD, it can be an important routine laboratory test to screen for mitochondrial dysfunction in BD. Indeed, more research is required to fully appreciate the nature of lactate as a potential biomarker for patients with BD.
The exact etiology of elevated brain lactate in BD is not fully understood. However, a core feature of mitochondrial disease is lactic acidosis. When cells are unable to meet their energy demand, pyruvate is converted to lactate to preserve the NAD+ pool, resulting in increased lactate levels and decreased pH. Indeed, approximately 80% of patients with mitochondrial disease present lactate accumulation. 24, 25 Factors that may contribute to lactate accumulation include altered rate of glycolysis, decreased intracellular oxygen, and lack of key mitochondrial subunits and cofactors, which leads to decreased oxidative phosphorylation activity. 26 A review of microarray studies demonstrated decreased mRNA levels of the core mitochondrial complex I subunits (NDUFV1, NDUFV2, NDUFS8, and NDUFS7) in post-mortem prefrontal cortex and hippocampus from subjects with BD, 27 leading several investigators to postulate that decreased complex I activity may be the cause of mitochondrial dysfunction observed in BD. 28 In vitro studies support this association and have found that rotenoneinduced complex I inhibition causes lactate accumulation in peripheral blood mononuclear cells. 25 These findings lead us to hypothesize that in BD, dysfunction in mitochondrial complex I through decreased expression of these catalytic core subunits may reduce electron flow through the electron transport chain, shifting energy metabolism to anaerobic glycolysis, leading to increased lactate production and decreased cellular energy output. While these results strongly point to the role of mitochondrial dysfunction in BD, no direct evidence up to now can support whether mitochondrial dysfunction is the cause of BD or a consequence that follows as a result of other biological processes. 28 In summary, we performed a systematic review of the literature and found a relatively consistent trend towards increased lactate in the brain and CSF in patients with BD. Meta-analysis of MRS studies revealed nearly significant increased levels of brain lactate in patients with BD. While heterogeneity is high, further studies with larger sample sizes and standardized methodologies across laboratories are needed to identify and validate lactate in BD. Beyond lactate, other bioenergetic markers should be thoroughly studied in larger BD sample sets to better understand the role of mitochondrial dysfunction in BD. These results could revolutionize the current diagnostic practices in the clinic and improve patient care.
